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ABSTRACT  
 
Despite strong anti-smoking efforts, at least 12% of American women cannot quit smoking when 
pregnant resulting in more than 450,000 smoke-exposed infants born yearly. Smoking during 
pregnancy is the largest preventable cause of childhood respiratory illness including wheezing 
and asthma. Recent studies have shown a protective effect of vitamin C supplementation on the 
lung function of offspring exposed to in utero smoke in a non-human primate model and an 
initial human trial. Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant Lung 
Function (VCSIP) is a randomized, double-blind, placebo-controlled trial to evaluate pulmonary 
function at 3 months of age in infants delivered to pregnant smokers randomized to 500 mg/day 
of vitamin C versus placebo during pregnancy. Secondary aims evaluate the incidence of 
wheezing through 12 months and pulmonary function testing at 12 months of age. Women are 
randomized between 13-23 weeks gestation from clinical sites in Portland, Oregon at Oregon 
Health & Science University and PeaceHealth Southwest Medical Center and in Indianapolis, 
Indiana at Indiana University and Wishard Hospital. Vitamin C supplementation occurs from 
randomization to delivery. Monthly contact with participants and monitoring of medical records is 
performed to document medication adherence, changes in smoking and medical history, and 
adverse events. Pulmonary function testing of offspring occurs at 3 and 12 months of age and 
incidence of wheezing and respiratory illness through 12 months is captured via at least 
quarterly questionnaires. Ancillary studies are investigating the impact of vitamin C on placental 
blood flow and DNA methylation. 
KEYWORDS: 
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Lung development 
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Forced expiratory flows 
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1. Introduction  
Smoking during pregnancy is the largest preventable cause of childhood respiratory 
illness1-3 and is a large public health issue since more than 50% of smokers who become 
pregnant continue to smoke despite the Surgeon General’s warning of the associated health 
problems.4;5 This equates to at least 12% of American women continuing to smoke  when 
pregnant, resulting in more than 450,000 smoke-exposed infants born yearly.6  Maternal 
smoking during pregnancy adversely affects lung development as seen by lifelong decreases in 
pulmonary function and increased risk of wheezing, respiratory tract infections, and asthma.1;2  
Nearly 20% of expenditures for childhood respiratory illness are caused by maternal smoking in 
the United States (US), amounting to over $1 billion annually in current health care dollars.7 
Although in  utero damage caused by tobacco smoke is preventable with smoking cessation, 
the reality is that smoking is a unique morbidity in that it is addictive and heavily advertised; 8-10 
moreover, individuals with certain genotypes have a significantly increased likelihood of nicotine 
addiction and failure to quit.11-13 Statistics from the Center for Disease Control show that 
decreases in smoking rates during pregnancy have plateaued and rates have even increased in 
some states, especially among younger women.14  Thus, finding ways to lessen the effect of 
smoking during pregnancy is of great public health importance. 
Recent studies have shown a protective effect of vitamin C supplementation on the lung 
function of offspring exposed to in utero nicotine/ smoke in both a non-human primate model 15 
and an initial trial in humans16 measuring newborn pulmonary function tests. However, one of 
the key effects of maternal smoking is a decrease in the forced expiratory flows17-20 (FEFs) of 
the offspring which was not measured in the aforementioned initial clinical trial. This report 
describes the development and methodology for the VCSIP (“Vitamin C to Decrease the Effects 
of Smoking in Pregnancy on Infant Lung Function”) study (ClinicalTrials.gov number 
NCT01723693), a randomized, double-blind, placebo controlled intervention of vitamin C 
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supplementation  to pregnant smokers with measurements of their offspring’s forced expiratory 
flows at 3 months of age as the primary outcome. VCSIP (www.vcsip.com) is supported by a 
R01 HL105447 from the National Heart, Lung, and Blood Institute with co-funding from the 
Office of Dietary Supplements. 
2. Background studies 
Newborns of smokers have decreased pulmonary function when measured after delivery 
and before significant exposure to postnatal smoke, confirming the importance of in utero 
exposure.
21;22
 These changes include decreases in FEFs, tidal breathing parameters, and 
respiratory compliance.
16;20-23
 Decreased pulmonary function early in life is associated with 
increased respiratory illnesses early in life, and maternal smoking during pregnancy is a major 
contributor to these adverse respiratory outcomes.24-27   Since pulmonary function tracks from 
infancy to early adulthood along percentiles established very early in life, it is critical to develop 
early life strategies to maximize lung growth and development, which begins early in gestation.22 
Our underlying hypothesis is that the effect of in utero smoke exposure on lung 
development and offspring lung function is mediated by oxidant mechanisms and therefore can 
be prevented by maternal vitamin C supplementation. A primary mediator of smoking-induced 
oxidant injury is nicotine.28-31  This is supported by data shown in Figure 1, in which prenatal 
nicotine exposure in pregnant non-human primates leads to decreased pulmonary function of 
the offspring similar to that seen in infants born after in utero smoke exposure 15,32 and 
discussed in a recent review.
33
 In the non-human primate model, maternal vitamin C 
supplementation significantly lessened the effects on pulmonary function, while decreasing the 
effects of nicotine on lung surfactant and elastin expression.15 
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Figure 1. Forced expiratory flows in non-human primates treated as shown (Mean ± SEM). 
 
 
 
 
 
 
 
*p< 0.05  for overall comparison of Nicotine-treated group to control and Nicotine + vitamin C-
treated groups by MANOVA.  FEF25%-75% = the average flow between 25% and 75% of 
forced expired volume. N= 20 total animals. Used by permission from Proskocil et al.15 
 
Based on the above results, we performed an initial study16 of the potential for 
supplemental vitamin C to block the effects of maternal smoking on offspring respiratory health. 
In this study, 159 pregnant smokers were randomly allocated in a double blind design to an 
additional 500 mg of vitamin C per day versus placebo, alongside a reference group of pregnant 
nonsmokers. Within 72 hours of age, newborn pulmonary function testing was done to assess 
tidal breathing flows of the time to peak tidal flow to expiratory time (TPTEF: TE) and passive 
respiratory system compliance (Crs). As shown in Table 1, maternal smoking during pregnancy 
was associated with decreases in TPTEF: TE, Crs, and Crs/kg (Crs normalized for newborn’s 
weight in kilograms), and the supplemental vitamin C blocked these decreases.16 
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Table 1. Newborn pulmonary function tests after in utero vitamin C to randomized smokers 
 
Newborns of 
nonsmokers 
(n=76)
a
 
Newborns of 
placebo 
treated 
smokers 
(n=83) 
Newborns of 
vitamin C 
treated 
smokers 
(n=76) 
Mean Difference (95% 
CI)  
(Vitamin C- Placebo) † 
P value† 
TPTEF:TE* 0.399 ± 0.077 0.345 ± 0.078 0.383 ± 0.084 0.036 (0.011 to 0.062) 0.006 
Crs/kg* 
(mL/cmH2O/kg) 
1.36 ± 0.30 1.20 ± 0.24 1.32 ± 0.30 0.11 (0.02 to 0.20) 0.01 
Total Crs* 
(mL/cmH2O) 
4.46 ± 1.10 3.92 ± 0.81 4.16 ±1.13 0.32 (0.02 to 0.62) 0.04 
Abbreviations: Crs, passive respiratory compliance; TPTEF:TE, ratio of time to peak tidal 
expiratory flow to expiratory time;  *Mean ± SD. a Nonsmokers are reference group only and not 
included in formal statistical analysis; † Values adjusted for gestational age at randomization, 
birth weight, and gestational age < 37 weeks. Used by permission from McEvoy et al.16 
 
The incidence of wheezing through 1 year of age as assessed by a standardized 
respiratory questionnaire in the infants of smokers allocated to supplemental vitamin C versus 
placebo was significantly decreased (Table 2).16 
Table 2. Respiratory outcomes in randomized infants through one year of age 
 
Newborns of 
non smokers 
(n=70)
a
 
Newborns of 
placebo treated 
smokers (n=77) 
Newborns of 
vitamin C treated 
smokers (n=70) 
Relative Risk 
(95% CI)* 
P value * 
At least 1 
episode of 
wheeze, No.(%) 
19 (27) 31 (40) 15 (21) 0.56 (0.33 to 0.95) 0.03 
Medication for 
wheeze, No.(%) 
7 (10) 17 (22) 9 (13) 0.56 (0.27 to 1.18) 0.13 
a Nonsmokers are reference group only and not included in formal statistical analysis; * Values 
adjusted for gestational age at randomization, birth weight, and gestational age < 37 weeks. 
Used by permission from McEvoy et al.16 
 
Although our initial study showed significantly improved newborn pulmonary function 
tests (PFTs) in the offspring of smokers allocated to vitamin C, we did not measure forced 
expiratory flows (FEFs) of the offspring which are considered the most sensitive measure of 
peripheral airway function. 20;34;35 It is difficult to measure FEFs in the newborn period due to 
instability of newborn lung volumes in the first weeks of life, sedation needs, and separation 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
from family. In order to assess pulmonary FEFs, we initiated a larger, multicenter randomized 
clinical trial (VCSIP) that includes measures of FEFs and other clinical signs and symptoms of 
infant respiratory health through one year of age. We are measuring FEFs at 3 months of age to 
balance the need to minimize possible side effects from the required chloral hydrate sedation 
with postnatal smoke exposure.36-38  With the addition of Indianapolis, Indiana, a second 
geographically distinct study location, this new trial includes a more diverse population. It also 
robustly examines clinical outcomes, specifically the measurement of FEFs at 3 and 12 months 
of age and the incidence of wheeze through one year of age among infants born to pregnant 
smokers randomly allocated to vitamin C versus placebo.  
3. Study design and methods 
3.1. Study aims  
The primary aim of the VCSIP trial is to determine if vitamin C supplementation as 
compared to placebo improves pulmonary function, measured by forced expiratory flows and 
specifically FEF75 (forced expiratory flows at 75% of forced vital capacity (FVC)) at 3 months of 
age, in infants delivered to mothers who continue to smoke cigarettes at least through the first 
trimester of pregnancy.  We hypothesize that vitamin C supplementation during pregnancy will 
block the adverse effects of maternal smoking on infant pulmonary function measured at 3 
months of age in infants born to pregnant smokers.  
A secondary aim is to compare the incidence of wheezing through 12 months of age in 
infants of mothers allocated to vitamin C versus placebo during pregnancy. We hypothesize that 
vitamin C supplementation during pregnancy will decrease wheeze in the first 12 months of life 
in offspring of smokers. An additional secondary aim is to demonstrate improved pulmonary 
function at 12 months of age in infants delivered to pregnant smokers who are allocated to 
supplemental vitamin C versus placebo during pregnancy as assessed by forced expiratory 
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flows. We hypothesize that vitamin C supplementation during pregnancy blocks the adverse 
effects of maternal smoking on infant pulmonary function measured at 12 months of age (forced 
expiratory flows) in infants born to smoking mothers.   
 
3.2. Study design summary (Figure 2) 
The study is a placebo-controlled, double-blind randomized trial conducted at the 
following clinical locations: Portland, OR metropolitan area (clinics delivering at Oregon Health & 
Science University (OHSU) and PeaceHealth Southwest Medical Center) and Indianapolis, IN 
(recruiting at Indiana University and Wishard Hospital).  After screening, consent, and 
successful completion of a run in phase, pregnant smokers less than 23
0
/7 weeks of gestation 
are randomized to one of two groups: Vitamin C (500 mg)/day or matching placebo. Smoking 
cessation is actively encouraged at each prenatal visit. During pregnancy, women are monitored 
with a set of serial biomarkers to assess nicotine exposure and medication adherence including 
fasting plasma ascorbic acid levels, urine cotinine levels, smoking questionnaires, pill counts, 
and exhaled carbon monoxide levels. Adverse events are monitored through delivery for 
mothers, and through 1 year of age for infants. Pulmonary function tests are performed at 3 and 
12 months of age and the offspring respiratory history is documented at least quarterly through 
12 months of age. 
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Figure 2. The VCSIP Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Did not meet criteria 
Decline consent 
Fail run in period 
Randomization of pregnant smokers 
500mg Vitamin C + PNV Placebo + PNV 
Birth 
 Delivery outcomes 
  Cord blood, placenta 
  Infant hair and buccal swabs, maternal hair 
  
Consent at  ≤216/7 weeks gestational age 
Enter run in period 
  Meet research personnel at prenatal appointments  
 Monitor adverse events, health history 
 Monthly smoking history, capsule count, & refills 
 Plasma ascorbic acid & urine cotinine on two visits  
Pass run in period 
Secondary Outcome # 1: Wheezing via at least quarterly 
respiratory questionnaire through 12 months of age 
Secondary Outcome #2: 12 month PFT 
Primary Outcome: 3 month PFT  
Identify & screen eligible pregnant smokers  
Abbreviations: PNV: prenatal vitamin; PFT: pulmonary function test 
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3.3. Study design population 
Potential study participants are pregnant women who report cigarette smoking at ≤216/7 
weeks and are receiving care at clinics affiliated with the following hospital locations: OHSU 
(Portland, Oregon), PeaceHealth Southwest Medical Center (Vancouver, Washington), Wishard 
or Indiana University (IU) Hospitals or surrounding clinics (Indianapolis, Indiana) and meet other 
eligibility criteria at randomization as follows.  
3.3.1. Inclusion criteria (applied to pregnant women at randomization) 
1. Singleton gestation 
2. >15 years old 
3. Gestational age between 130/7 and 22
6/7 weeks based on clinical information and 
ultrasound 
4. Receiving prenatal care at clinics delivering at OHSU, PeaceHealth Southwest 
Hospital, Wishard, or Indiana University (IU) Hospital or surrounding clinics 
5. Current cigarette smoking of at least 1 cigarette in last week 
6. English speaking  
 
3.3.2. Exclusion criteria at randomization 
1. Gestational age ≥ 23 0/7 weeks 
2. Multiple gestation 
3. Documented major fetal congenital anomalies  
4. Current use of illicit drugs  
5. Current alcohol abuse as defined by questionnaire (≥ 3 drinks on ≥ 5 days per 
week during this pregnancy or any hospitalization for alcohol abuse or 
complications of alcohol abuse or outpatient visit for acute alcohol intoxication 
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during the past year) 
6. Use of vitamin C (≥ 500 mg/day) > 3 days per week since LMP 
7. Refusal to abstain from vitamin or supplements containing significant vitamin C 
other than those provided through the study or approved by study staff 
8. History of kidney stone  
9. Insulin dependent diabetes   
10. Complex maternal medical conditions 
11. Participation in other conflicting research projects 
12. Unable to demonstrate stable method of communication or incarcerated 
13. Pregnancy by in-vitro fertilization 
14. Plan to terminate pregnancy 
15. Failure of run in phase / medication adherence trial (see section 3.7 below) 
16. Failure to return in designated period during run-in 
17. BMI > 50 at screening 
 
3.4. Intervention: vitamin C supplement 
VCSIP is testing a supplemental ascorbic acid (vitamin C) dose of 500 mg per day 
versus placebo. The vitamin C and placebo medications are manufactured in organoleptically 
similar tablets at an outside site (Magno-Humphries Laboratories INC, Tigard, OR) and 
dispensed through the research pharmacy at OHSU.  Each vitamin C tablet contains 500 mg of 
ascorbic acid powder; the placebo tablet contains microcrystalline cellulose and 100 mg of citric 
acid to mimic the taste of vitamin C.  The tablets are otherwise identical in appearance, size and 
shape. Both medications are  dispensed in 21 and 100 tablet quantities (21 count during the run 
in/adherence period and 100 count during the treatment period). All pregnant women also 
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receive 60 mg of vitamin C through a standard prenatal vitamin (Prenavite, Rugby Laboratories, 
Duluth, GA, 100 count) supplied to them by the study.  
Vitamin C is a common antioxidant and the Institute of Medicine states that daily doses 
of up to 2000 mg are likely to pose no risks of adverse effect.39  A concern over a potentially 
harmful effect of supplemental vitamin C during pregnancy on prematurity has been described.  
A 2005 Cochrane review of vitamin C supplementation in pregnancy concluded that women 
supplemented with vitamin C were at an increased risk of preterm birth (RR 1.38, 95% CI 1.04 
to 1.82, 3 trials, 583 women).40 This meta-analysis was significantly influenced by one trial,41  
the only trial of the three to demonstrate this pattern of increased preterm deliveries in the 
treated group. Of note, 43% of the randomized patients were smokers in this study,41 and there 
was no significant difference in the incidence of prematurity within the subgroups of smokers by 
treatment group. A trial of 10,154 women who were allocated to vitamins C and E in pregnancy 
versus placebo did not show any significant difference in preterm births.42  Also, an updated 
2015 Cochrane review of vitamin C supplementation in pregnancy evaluating data from 16 
studies and 22,250 patients found no evidence of increased or decreased preterm delivery.43  
Our initial study16 also lends support for the safety of 500 mg of vitamin C daily in 
pregnancy as there was no significant difference in maternal, fetal, or neonatal adverse 
outcomes between the randomized arms. Similarly, there were no significant differences in 
prematurity or gestational age between babies born to smoking mothers randomized to vitamin 
C versus placebo. 
The 500mg daily dose of vitamin C is further justified within our initial trial16 showing that 
at 28-30 weeks of gestation, the vitamin C treated smokers had a higher average fasting plasma 
ascorbic acid level than the placebo-treated smokers (58.9 vs 39.8 µmol/L [95% CI for the 
difference between the means, 11.23-26.95]; p <0.001) which was comparable to the level of 
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57.8 µmol/L measured in the reference group of nonsmokers. This is congruent with data in 
non-human primates exposed to just nicotine, in which prenatal nicotine exposure also 
decreased ascorbic acid levels in both cord blood and amniotic fluid (Spindel, unpublished). 
Therefore we selected this dose of vitamin C to restore ascorbic acid levels in the pregnant 
smoker to be similar to that in the pregnant nonsmoker. This supplementation does not 
significantly increase vitamin C levels compared to the pregnant nonsmoker who is not 
consuming a supplement. 
 3.5. Identification/ screening for eligibility 
Recruitment is maximized by assigning a research coordinator to each clinical 
recruitment site to screen and consent eligible pregnant smokers. Women are recruited by 
provider referral and by self-referral from posted study flyers.  Additionally, research staff 
routinely query the clinics’ electronic medical records to identify obstetrical patients who fit initial 
eligibility criteria, including cigarette smoking, which is a standard question on all obstetrical 
intake forms.  
 
3.6. Counseling and enrollment 
The screening visit primarily occurs at the subject’s prenatal visit between 11 and 216/7 
weeks gestation.  At the screening visit, research staff  present a written description of the study 
and review eligibility criteria. Once eligibility is confirmed, informed consent is obtained prior to 
any study procedures.   
Because of the importance of emphasizing smoking cessation, research staff discuss 
this with the patient and provide a pregnancy-specific pamphlet. The 5 A’s for smoking 
cessation are assessed and documented: ask about tobacco use; advise every smoking patient 
to quit; assess willingness to make a quit attempt; assist in quit attempt; arrange for follow-up 
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and future support.44 We follow best practices and strongly encourage the patient to participate 
in a smoking cessation program; because of this protocol, we believe that this population may 
receive greater encouragement to quit smoking than the general population.  We included a 
specialist from the OHSU Smoking Cessation Center as a co-investigator on the study45;46 who 
trained research personnel about cessation techniques. Only women truly unable to quit 
smoking are involved in the study; a substantial proportion of pregnant smokers will stop 
spontaneously before they begin prenatal care and those who are active smokers at their first 
prenatal visit are less likely to change their smoking habits.47-49 If a patient indicates that she has 
quit smoking after randomization, this is noted and they are instructed to continue to take the 
study medication. 
3.7. Run-in phase 
This study includes a run-in phase. Upon consent, to exclude highly noncompliant 
subjects, patients enter into a medication adherence trial of 14 ± 7 days. The research 
pharmacy dispenses 21 days of the placebo medication, and all subjects are given an 
appointment to return within three weeks. Non-adherence is defined by failing to return for the 
subsequent visit within 14 ± 7 days or consuming < 75% of the required tablets. 
3.8. Gestational age determination 
Gestational age is first estimated by reviewing the results of the first available ultrasound 
examination. The minimum days required to complete the run-in are 7, thus women >22 weeks 
of gestation are too advanced to complete the run-in and be randomized prior to 23 weeks of 
gestation and are excluded.  When an ultrasound examination has not been performed, 
gestational age is estimated using available information and an ultrasound is scheduled. 
Gestational age is based on the earliest obstetrical ultrasound estimate as determined at each 
clinical center.   
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3.9. Randomization  
The second study visit includes assessment of the run-in phase (medication adherence 
trial). If the patient is adherent(≥ 75% tablets consumed and returns within 14 ± 7 days of first  
visit) the detailed smoking questionnaire is administered, fasting blood, urine, and hair samples 
are collected, an exhaled carbon monoxide test is done, and the patient is randomized into the 
study. See Table 3 for summary of procedures done at the various visits. 
Randomization is performed at the Data Coordinating Center (DCC) using permuted 
block randomization stratified by gestational age at time of randomization (< 18 weeks versus > 
18 weeks gestation) and clinical site (Oregon, Washington, or Indiana); we used random block 
size. Gestational age was selected for stratification to limit potential bias by spontaneous 
abortion or unequal distribution of gestational age among study arms. It is also a potentially 
critical covariate because of the effect of duration and total dose of vitamin C on the developing 
infant.  A randomization schedule is given to the research pharmacy for preparation of the 
medication to dispense to research subjects.  The study medication  is labeled with study 
identification and a consecutive study code for the patient, aligned with the randomization 
scheme. After confirming all relevant data in the database, an intervention assignment 
corresponding to the sequenced medication is returned to the study coordination. 
Participants are provided a bottle of study drug which contains 100 tablets of either 
vitamin C or placebo dispensed by the research pharmacies at the respective study locations. In 
addition, each participant is also dispensed a standard prenatal vitamin (Prenavite, Rugby 
Laboratories, Duluth, GA ) and instructed to take one study tablet daily and one prenatal vitamin, 
preferably with meals. Women are reminded frequently to bring medication bottles back to each 
study visit and at delivery. 
3.10. Prenatal visits/contact 
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After randomization, the research staff coordinates interval study visits with routine 
prenatal appointments that occur approximately every four weeks, then more frequently as 
delivery approaches. Smoking is assessed with a standardized questionnaire at each visit. Brief 
smoking cessation counseling as per the American College of Obstetricians and Gynecologists 
guidelines50 occurs and is documented at each prenatal visit.  Urine, maternal hair, fasting 
maternal blood samples and exhaled carbon monoxide levels are obtained at 26 ± 2 weeks, and 
32 weeks ± 2 weeks of gestation. Adherence with dispensed medication (vitamin C or placebo) 
is assessed via monthly pill count by VCSIP study staff and at return of each medication bottle 
dispensed. The research staff conduct monthly reviews of the electronic medical record to 
check for pregnancy complications.  
3.11. Delivery and follow-up visits 
Research personnel attend each participant’s delivery and collect cord blood and 
placenta samples. During hospitalization for delivery, study personnel collect infant 
anthropometric measurements, neonatal data, and maternal and newborn hair samples and 
buccal swabs. After delivery, research staff contacts participants every 3 months to inquire 
about the infant’s respiratory status via a standardized respiratory questionnaire. Subjects and 
their offspring are seen when the infant is 3 and 12 months of age for pulmonary function testing. 
At these visits the infant health, maternal smoking, and environmental smoke exposure 
assessments are done in person, hair samples are collected from both the mother and infant, an 
exhaled carbon monoxide measurement is obtained from the mother and buccal swabs are 
obtained from the infant. At the last visit the Ages and Stages Questionnaire51;52 and the study 
disposition form is completed. The study visits and contacts are outlined in Table 3 below. 
3.12. Participant retention 
Frequent, consistent, and personal contact is critical to retain this vulnerable population 
in a research protocol.53 Interval phone calls, text messages, and emails to patients are 
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employed monthly.  To maximize retention, multiple contact information is collected, private 
messaging through social media is utilized, and small travel reimbursements are provided. 
 
4. Outcome procedures / assessments  
The primary outcome of this study is the measurement of infant pulmonary function tests 
(PFTs) at 3 months of age, specifically, the measurement of forced expiratory flow at 75% of the 
expired volume (FEF75) using the raised volume rapid thoracic compression (RVRTC) 
technique. Secondary outcomes include: the measurement of forced expiratory flows at 12 
months of age; the incidence of wheezing through 12 months of age via at least quarterly 
documentation of respiratory symptoms and treatments; other measurements of FEFs obtained 
at the 3 month PFT, including FEF25-75, FEF50, and FEF85, and forced expiratory volumes 
including forced vital capacity (FVC), forced expired volume in the initial 0.4 sec (FEV0.4) and 0.5 
sec (FEV0.5) and the ratio of FEV0.5/FVC. 
4.1. Pulmonary function testing 
Forced expiratory flow measurements were chosen as the primary outcome in this study 
since they are the parameters of airway function shown to be most sensitive to the effects of 
maternal smoking in infants and most predictive of increased risk of future pulmonary disease. 
20;34;35
  All pulmonary function tests in the VCSIP study are performed in the controlled infant 
pulmonary function testing laboratory located at OHSU/Doernbecher Children’s Hospital, the 
James Whitcomb Riley Hospital for Children, or the PFT laboratory at Peace Health/ Southwest 
Medical Center. These laboratories are the few across the country equipped to perform this 
testing in infants and have a history of successful studies in the area of infant pulmonary 
function testing.16;54;55 All labs are staffed with skilled technicians who perform pulmonary 
function tests and sedation under physician supervision. Testing is performed following the 
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American Thoracic Society/ European Respiratory Society criteria for performance and 
acceptance 56 and measurements are reported as absolute values.  
Infant pulmonary function testing is performed at 3 months (the age range of testing 
allowed is 12 weeks up to 6 months of age) and at 12 months (range of 10 up to 15 months of 
age).  Since growth/length is an important determinant of the FEFs, the pulmonary function tests 
are performed as close as possible to 12 weeks and 12 months post term age. However, as 
testing cannot be done within 3 weeks of a respiratory illness, a time range for testing has been 
established.  
The same pulmonary function testing equipment is used at all sites (Jaeger/Viasys 
Master Screen BabyBoy; Yorba Linda, California). Operational procedures were rigorously 
calibrated across study sites according to the manufacturer’s directions and outlined explicitly in 
the study’s manual of operations. In addition, cross training and certification of PFT laboratories 
assures the same testing techniques and acceptance criteria are applied across sites. All PFT 
test results are reviewed by a blinded trained reviewer. The respective hospital pediatric 
sedation protocol is followed, and the infant is given 50 to 100 milligrams per kilogram of chloral 
hydrate by mouth, with a maximum dose of 1 gram. The parents are counseled about possible 
side effects and asked to sign a separate consent for sedation as per respective hospital policy, 
and are given patient discharge instructions. Adverse events are reported as outlined below. 
The results of the 3 and 12 month PFTs are faxed to the patient’s physician.   
4.2. Incidence of wheeze through 12 months of age 
To compare the incidence of wheezing between the infants of smoking mothers 
randomized to vitamin C and placebo, a detailed standardized infant respiratory questionnaire57 
is administered at least quarterly to the infant’s primary caretaker, either by phone or in person 
at the 3 and 12 month PFT. This questionnaire is the same as that administered quarterly in the 
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Vitamin D Antenatal Asthma Reduction Trial (VDAART) study57;58 in which one of the primary 
outcomes was the parental report of physician diagnosis of asthma or occurrence of recurrent 
wheeze in the child’s first 3 years of life. This questionnaire is used in the VCSIP to document 
the incidence of wheezing in the infants through one year of age by the caretaker and by doctor 
report, as well as other respiratory symptoms (lower respiratory infections), medications of 
interest including inhaled or oral bronchodilators and/ or steroids, and leukotriene modifiers and 
a clinician’s diagnosis of bronchitis, bronchiolitis and asthma.  
5. Sample collections  
5.1.Blood collection 
Fasting blood samples for ascorbic acid levels are collected from the mothers at 
randomization, at 26 ± 2, and at 32 ± 2 weeks of gestation, as a measure of medication 
adherence.  At one of these time points, additional blood is drawn for genotyping.  
 Plasma ascorbic acid levels are tightly controlled around steady state levels with 
transient peaks after oral intake therefore necessitating fasting levels.59;60 The sample at 
randomization will establish the baseline ascorbic acid level prior to beginning the study 
supplementation and the subsequent levels will allow us to confirm adherence to the medication 
and evaluate levels achieved for the study dose.  
At delivery, cord blood samples are collected to allow us to compare the ascorbic acid 
levels in the newborn to the maternal levels. A sample is also collected for genotyping. Near the 
time of delivery, women are customarily not allowed to eat, and study personnel request that 
they do not drink any liquid high in vitamin C in the hours prior to delivery. Study personnel 
carefully document the date and time of last study medication intake and dietary intake. 
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After obtaining consent, the mother and her infant are genotyped for the α5 nAChR 
D398N structural polymorphism (rs16969968), the decrease of function allele for GSTP1 
(rs1695), and for the null alleles for GSTM1 and GSTT1.  Remaining DNA is stored for further 
genetic analyses of smoking-induced changes. The α5 nAChR structural polymorphism 
(rs16969968) has been associated with increased risk of lung cancer, nicotine addiction, and 
chronic lung disease61 and in our initial study, offspring of mothers homozygous for this at risk 
allele had the greatest decrease in their PFTs, and the most benefit from the vitamin C 
supplementation.16 
The types of blood samples collected are shown in Table 3.  
5.2 Urine collection 
Urine samples are collected for assessment of cotinine at baseline, 26 ± 2, and 32 ± 2 
weeks of gestation. Within one hour of collection, the urine is aliquoted into eight cryovials and 
placed in -80°C freezer and shipped on dry ice to Dr. Eliot Spindel’s laboratory where it is stored in 
a  -80°C freezer until tested for cotinine levels with additional samples stored for future use.  
5.3. Exhaled carbon monoxide.  
Non-invasive measurements of exhaled carbon monoxide (CO) are obtained from the 
mother at baseline, 26 ± 2, and 32 ± 2 weeks of gestation and at the 3 and 12 month PFTs 
(Smokelyzer, Bedfont Scientific, London, UK) 62 to assess recent cigarette smoke exposure. 
The mother is instructed to inhale deeply and hold her breath for 15 seconds and then blow into 
the disposable mouthpiece of the Smokerlyzer until her lungs are completely empty. The 
highest level of the parts per million (ppm) of carbon monoxide and the percent of 
carboxyhemoglobin (COHb) are then recorded. Detection of the exhaled CO is performed by an 
electrochemical sensor which has a range of detection of 0-500 ppm, a sensitivity of 1 ppm and 
repeatability of readings of ± 3%. Nonsmokers who have no exposure to second hand smoke 
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having readings of < 2 ppm. Calibration of the equipment is performed prior to study initiation 
and every six months as per the manufacturer specification. 
5.4 Hair nicotine from mothers and offspring 
 Hair nicotine gives a longer representation of smoke exposure with hair growing on 
average 1 cm per month and the hair closest to the scalp representing the most recent 
exposure to nicotine.  Small samples of the mother’s hair are taken at entry into the study.  
Additionally, mother and infant hair samples are collected at delivery, 3 months and 12 months 
of age. An area for hair collection, ideally on the occiput is identified. The hair is sectioned off by 
hand and least 20 strands are gently cut with scissor as close to the scalp as possible. A tie is 
placed on the cut end to identify the root, and the sample is placed in a piece of tissue paper 
and then into an anti-static bag and stored at room air until processed.  
5.5 Placenta 
The placenta is processed as soon as possible after delivery (within two hours) by study 
personnel. It is weighed on the same balance at each location and the maximum diameter (x-
axis) and minimum diameter (y-axis) recorded to the nearest millimeter. It is then positioned with 
fetal side facing up and fetal membranes folded around the edge and the four quadrants of the 
placenta are sampled twice per quadrant using a stainless steel placenta biopsy tool. Each 
tissue sample is divided in half with one sample flash frozen and the other sample placed into 
either RNA later or neutral buffered formalin to be fixed in paraffin. The tissue in the RNA later 
tubes are incubated at 4°C for 16-72 hours and then transferred to tin foil and stored at -80°C.  The 
time of all sampling processing is documented and samples are placed at -80°C until transferred 
on dry ice to storage at -80°C in the sample repository at Dr. Spindel’s laboratory for future study.  
5.6 Buccal swabs on offspring 
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Buccal swabs are collected on the offspring at birth, 3 months, and 12 months of age to 
investigate DNA methylation patterns that may mediate subsequent respiratory disease after 
prenatal exposure to nicotine.63  Buccal swabs are taken using Epicentre Catch-All wrapped soft 
foam swabs.  Swabs are performed by rolling the swab on the inside of  the infant’s cheek, 
approximately 10-20 times on each side, making certain to roll the brush over the entire 
cheek.  After collection the swab is placed in the collection tube and stored at –20°C.  To 
increase yield of cells a separate swab is used for each cheek surface and each cheek is 
swabbed separately twice.  
6.  Sample assays/analysis 
6.1. Ascorbic acid/green top heparin tubes.  
Seven mL of blood are collected and the contents of the tubes are gently inverted eight to 
ten times immediately after collection, are protected from the light by either wrapping in tin foil or 
inverting a box over the tube, and placed in wet ice for up to a maximum of 60 minutes until the 
tubes are centrifuged.  The blood is spun at ≤ 1300 x g at 4°C for 10 minutes in a refrigerated 
centrifuge to separate blood cells from plasma. Four aliquots of 750 µL of plasma are then pipetted 
into separate 2 mL flip-cap microcentrifuge tubes and placed into a -80°C freezer at Dr. Spindel’s lab 
until shipped on dry ice to the Linus Pauling Institute for analysis.  All blood samples are 
processed as soon as possible and within 2 hours of sample collection; a minimum plasma 
sample of at least 200 µL is required for ascorbic acid assay.  
Plasma ascorbic acid levels are performed at the Linus Pauling Institute, Oregon State 
University. Human plasma is stabilized by the 1:1 (v/v) addition of 15% perchloric acid (PCA; 
EMD Millipore, Billerica, MA) containing 1mM diethylenetriaminepentaacetic acid (DTPA; 
Sigma-Adrich, St. Louis, MO) to chelate excess iron. Acid extracts are prepared for ascorbate 
analysis using high performance liquid chromatography as previously described.64 Briefly, 
extracts are diluted in sodium acetate/methanol/water mobile phase (0.3%/7.5%/92% w/v) 
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containing Q12 ion pairing reagent (Regis Technologies, Morton Grove, IL) and pH-adjusted 
with 2.58 M KH2PO4 buffer (pH 9.8). Samples are separated on Watters 2695 using an LC-8 
Supelco column (Sigma-Aldrich, St. Louis, MO) under an applied potential of 600 mV using an 
electrochemical detector (BAS, West Layfayette, IN). Under these conditions, both urate and 
ascorbate are resolved and quantified by comparisons to authentic standards with a detection 
limit of approximately 10 nM (inter-assay CV <15%). For human plasma samples, urate values 
are used to normalize ascorbate values to minimize any variations detected (intra-assay CV 
<5%).  
6.2 Urine cotinine assay 
Urine analysis for cotinine 65 are performed with a widely used ELISA (Enzyme Linked 
Immunesorbant Assay) kit following the vendor’s protocol (Calbiotech, Sping Valley, CA)  in Dr. 
Eliot Spindel’s laboratory. The detection limit is 2 ng/mL.  
6.3 Genotyping processing lavender-top tubes (EDTA) for whole blood 
 
Two 3 mL lavender-top (EDTA) tubes are used to collect blood for maternal and infant 
genotyping. Two mL of blood are placed in each tube and gently inverted eight to ten times 
immediately after collection. The samples are then placed directly into a -80º C freezer and 
shipped to the Spindel laboratory and stored in -80º C freezers.  
Genotyping for the α5 nAChR D398N structural polymorphism (rs16969968) and the 
decrease of function allele for GSTP1 (rs1695) are performed using predesigned qPCR SNP 
genotyping reagents from Thermo Fisher (Applied Biosystems, Foster City, CA).  Genotyping of 
the mothers and infants for the null alleles for GSTM1 and GSTT1 are performed using 
predesigned qPCR copy number assays from Applied Biosystems.  Remaining DNA is stored 
for further genetic analyses of smoking-induced changes. Genomic DNA is isolated from 0.35 
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mL of blood using automated protocols from Promega (Madison, WI) or Qiagen (Hilden, 
Germany). 
6.4. Hair nicotine 
Hair nicotine is determined by a modification of the methods of Hegstad et al 66 and 
Pichini et al67 by tandem mass spectrometry (LC-MS/MS) using deuterated internal standards. 
7. Quality of study medication and blinding  
Maintaining the integrity of randomization and blinding is the most important asset of the 
study and is the primary goal of the DCC as outlined above. To ensure integrity of the 
medication preparation, potency testing of the vitamin C tablets was done prior to the initiation 
of the study.  To assist in assessing the effectiveness of blinding, participants are asked at the 
12 month PFT which treatment group they believe they were assigned during the study.   
7.1.Assessment of medication adherence- Pill counts at prenatal visits 
 Patients are reminded frequently to bring their study medication in to every prenatal visit 
and at delivery. Adherence is calculated based on number of study medication tablets 
dispensed and number of study medication tablets returned (number of tablets taken divided by 
number of tablets that should have been taken X 100 = percent compliant).  However given the 
greater reliability of a biomarker to detect adherence in comparison to pill count, we selected 
ascorbic acid levels as our primary measure of adherence. 
8. Analysis plan and statistical power 
8.1. Analysis plan 
This is a randomized, double blinded, multi-center, placebo controlled clinical trial of 
supplemental vitamin C to pregnant smokers to improve pulmonary function and decrease 
wheeze in their offspring. The primary outcome is the measurement of FEF75 at 3 months of 
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age. Secondary outcomes include the incidence of wheeze through 12 months of age and 
FEF75 at 12 months of age.  
The statistical analyses are based on intention to treat. The primary analysis of the 
FEF75 will compare the FEF75 of infants born to mothers randomized to Vitamin C versus 
placebo, using regression analysis adjusting for the infant’s sex, race, and age and length at the 
time of FEF75 measurement, and the stratification variables (site and gestational age at 
randomization i.e. ≤18 weeks versus > 18 weeks). FEFs are highly correlated with body length 
and are a standard component in the interpretation of FEF75 and similar measures.
54;56. Since 
FEF75  is not normally distributed, we will use the natural logarithmic transformation of FEF75 for 
the primary analysis to reduce expected skewness.68  Assessment of outliers and influential 
points will be conducted and reported. 
8.2. Statistical power 
The trial was designed to detect a 15% increase in FEF75 at 3 months of age in the 
vitamin C supplemented versus placebo group. The estimates of sample size and power were 
obtained using our experience in the initial vitamin C study16 and on measures of variability of 
FEF75  in 155 healthy infants of smoking and nonsmoking women as published by co-
investigator, Dr. Tepper.54  The estimated standard deviation from a regression model 
comparing infants of non-smoking to smoking women was 0.28, using the natural logarithm of 
FEF75 as the outcome. The estimated increase in FEF75 for infants of nonsmoking women was 
17.6% greater than that for infants born to smoking women. For power calculations, we use this 
value along with increases in FEF75 of 15.0% and 12.5%.  
The PFT data from our initial study showed an increase of 11% (p<0.01) in the 
measurement of the time to peak tidal flow to expiratory time (TPTEF:TE) and a 10% increase 
in respiratory compliance normalized per kilogram (Crs/kg) between babies born to smoking 
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pregnant women randomized to vitamin C versus placebo. Both have clinical significance, 
particularly the change in TPTEF:TE.  A decreased TPTEF:TE measured in the initial weeks of 
life has been shown to precede and predict wheezing.15;21;34;69;70 The current VCSIP study 
employs FEFs, a more sensitive and reproducible measure of peripheral airway function.20;34;35 
Thus, we powered VCSIP to show a 15% difference in FEF75 between randomized patients. We 
chose this as clinically significant as the NHLBI asthma guidelines71 define a positive response 
to a bronchodilator as increases in FEV1 of this magnitude. Table 4 shows the sample sizes 
needed to show a 15% difference in FEF75 with a 80% and 90% power at a significance level 
0.05 using the estimated standard deviation of 0.28 as published from Jones and Tepper et al.54 
as well as a 90% upper confidence bound for the standard deviation, 0.30 using the chi-squared 
distribution of the estimated SD. Calculations are based on two-sided tests. 
Table 4. Sample sizes per group for FEF75 with 90 (80%) power using a two-sided test at level 
of 0.05. 
Mean difference 
in ln(FEF75) 
between infants 
in the vitamin C 
and the placebo 
groups. 
Ratio of FEF75 
for infants in 
mothers 
allocated to 
vitamin C relative 
to placebo. 
Sample size per 
group needed for 
90% (80%) 
power using the 
estimated SD of 
0.28. 
Sample size per 
group for 90% 
(80%) power 
using estimated 
90% upper 
confidence bound 
for SD (0.30). 
Sample size per group 
for 90% (80%) power 
using estimated 90% 
upper confidence bound 
for SD: 0.30 and 
assuming 4%  
non-adherence/crossover 
0.162 17.6% 64 (48)  75 (56) 82 (61) 
0.1398 15.0% 86 (64)  100 (75) 109 (82) 
0.1178 12.5% 120 (90) 140 (105) 152 (114) 
 
Conservatively, using the 90% upper confidence bound for the standard deviation, with a 
sample size of 100 mothers per group, we would have 90% power at level 0.05 to detect an 
increase of 15% in FEF75  for infants randomized to Vitamin C compared to those randomized to 
placebo and measured at three months of age. Adjusting for adherence data from our initial 
study showing only 4% of patients were non-compliant (took <50% of their medications), we 
increased our sample size to 109 patients per group studied at the 3 month PFT. Figure 3 below 
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shows our original projected study recruitment to achieve this desired sample size based on 
recruitment and cohort loss data from our initial randomized trial. 
Figure 3. Original projection of study recruitment 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
With regard to aim 2, preliminary data from our initial study on 80 infants from mothers allocated 
to vitamin C versus placebo suggested a difference in the incidence of  wheezing in their infants 
through 1 year of age:  placebo 48%, vitamin C 26% (p=0.06).  The incidence of wheezing at 1 
year of age in 101 infants of pregnant smokers randomized to the placebo was 45% which was 
similar to that reported by Dezateux.35  The incidence of wheezing in infants of non-smoking 
mothers in our pilot study was 14%.  Based on these data from our initial study and from that of 
Dezateux,35 Table 5 shows the sample sizes needed at delivery to detect various hazard ratios 
212 Infants Followed Through 
12 Months 
Projected VCSIP Recruitment 
278 Smokers Consented 
242 Smokers Randomized 
226 Infants Studied at  Birth 
218 Infants with 3 Month PFT 
12.6% loss 
6.3% loss 
3.3% loss 
7% loss 
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for wheezing through 1 year of age with 80% and 90% power with a two-sided significance level 
of 0.05. Calculations are based on the log-rank test.  We estimate that our targeted sample size 
of 113 infants per group at delivery allows excellent power of 80-90% for detection of hazard 
ratios of  0.45-0.50 with a 0.5-1% drop-out per month.    
 
Table 5. Sample sizes per group to detect wheezing incidence with 80% (90%) power  
Proportion 
wheeze in 
placebo group 
within first year 
Proportion 
wheeze in 
vitamin C 
group within 
first year 
Hazard Ratio 
vitamin C group 
relative to 
placebo 
Sample size per group 
needed at delivery for  
90% (80%) power with 
drop-out of 0.5% per 
month  
Sample size per group 
needed at delivery 
for  90% (80%) power 
with drop-out of 1% 
per month  
0.48 0.14 0.23 35 (27) 36 (28)  
0.48 0.20 0.34 57(43) 59 (45)  
0.48 0.26 0.46 99 (74) 101 (77)  
0.45 0.14 0.25 41 (32) 42 (33)  
0.45 0.20 0.37 71 (54) 73 (55)  
0.45 0.26 0.50 131 (99) 135 (102)  
0.40 0.14 0.30 54 (44) 58 (45)  
0.40 0.20 0.44 108 (81) 111 (84)  
 
9. Trial Monitoring 
An external Data Safety and Monitoring Board (DSMB) was appointed by the National 
Heart, Lung, and Blood Institute (NHLBI) and consists of experts in the fields relevant to this 
study. The DSMB approved the trial protocol. During the conduct of the study, the DSMB 
monitors trial performance and safety, and protocol adherence. The DSMB receives quarterly 
reports detailing adverse events, patient recruitment, cohort retention, medication adherence, 
baseline patient characteristics, and center performance information with respect to data quality, 
timeliness of data submission and protocol adherence (in addition to safety and efficacy data). It 
also approves all manuscripts prior to submission for peer review. VCSIP has approval  by the 
Institutional Review Boards of each of the participating Clinical Coordinating Centers and the 
Data Coordinating Center.   
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Monitoring the safety of the vitamin C dose is a high priority.  We actively monitor the 
following:  inability to tolerate ingestion of the study medication; any allergic or adverse 
responses; the unlikely development of kidney stones; confirmation of adherence to exclusion 
criteria of no other vitamin C supplementation aside from study medication and supplied 
prenatal vitamin; incidence of any complications of pregnancy; incidence of intrauterine growth 
retardation and large for gestational age; incidence of prematurity and associated respiratory 
morbidities; presence of any congenital malformations.  This is done at each prenatal visit (at 
least monthly) and at delivery. The study medication is terminated under the following 
conditions: side effect presumed to be from study medication; termination of pregnancy; 
urolithiasis; serious complication of pregnancy where continuation of study medication is 
deemed inappropriate or impossible. 
10. Adverse event reporting 
All subjects are monitored for adverse events (AEs). AEs in this study are identified by 
interviewing the subject, review of the subject’s electronic medical record, and by physical 
exam/observations (including vital signs monitoring during sedation). Research staff review AEs 
in real-time with study principal investigators to grade the AEs as to their expectedness and 
attribution (unrelated, possibly, probably or definitely related to the protocol) and AE/SAE forms 
are completed and faxed to the DCC. All serious adverse events (SAEs) and unexpected 
problems (UPs) are reported by clinical sites to the DCC within one business day. All AEs are 
reported within 7 days. The DCC evaluates each event and determines reporting requirements. 
All SAEs and UPs that are deemed related and unexpected require expedited reporting and are 
reported to the DSMB within 7 business days. In addition, the following has expedited reporting: 
maternal death through delivery; fetal loss, neonatal or infant death through 1 year of age; any 
sedation related event requiring significant resuscitation and/or hospitalization. All other SAEs 
are reported to the DSMB within 30 business days and all other AE’s are summarized quarterly 
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for the DSMB.  Summary AE and SAE reports are submitted to the respective clinical site IRBs 
annually. 
 
11. Data collection, forms and entry 
Data for the VCSIP study is collected on standardized case report forms with 
independent double data entry into a REDCap database. Site personnel complete the paper-
based case report forms, perform pre-processing checks for completeness and consistency of 
key data fields, and independently enter data into the study database via secure web-based 
forms. Duplicate data entry occurs at the DCC with adjudication as required.   
12. Data management 
Data is collected within each study site by a combination of study-specific forms that 
capture clinical information not routinely recorded in patient charts, by abstraction of standard 
clinical information and outcomes from the records of patients, and by patient self-reports.  The 
timely entry of data and faxing of case report forms is monitored by maintaining a study 
calendar using the database’s study and participant calendar feature and reviewing expected 
visits, forms, and specimens on a weekly basis. 
The discrepancy management process includes a variety of important data quality tasks. 
These include running production edit checks, reviewing data discrepancies produced by edit 
checks, generating queries, resolving discrepancies, and updating any relevant data in the 
database. In addition to the computerized checks, the data management staff conduct manual 
reviews of the data throughout the study.  All discrepancies identified are reviewed by the DCC 
staff who then either resolve the discrepancies or forward queries to each site for clarification or 
resolution on data clarification forms. The sites return the data clarification forms after 
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resolution. The data team then modifies the data with a full audit trail generated for each 
modification. 
 
13. Ancillary studies 
13.1.Placental blood flow 
Preliminary data in non-human primates has recently demonstrated decreased placental 
blood flow in nicotine-exposed fetal monkeys and has demonstrated that supplemental vitamin 
C decreases this effect.72  Based on this data, an ancillary study funded NHLBI with co-funding 
from the Office of Dietary Supplements was obtained. In this ancillary study, extra ultrasound 
views are done during a routinely ordered prenatal ultrasound to specifically measure umbilical 
blood flow using color and pulsed/wave Doppler, uterine artery and placental volume blood flow. 
73;74  These extra views are done at 34 ± 2 weeks of gestation in a subset or randomized 
smokers in the main study.   
13.2 Placenta and offspring buccal swabs analysis 
Epigenetic changes that occur in utero may explain the lifelong detrimental health effects 
observed in individuals whose mother smoked during pregnancy. Maternal smoking during 
pregnancy has been associated with both modification of specific genes75;76 and changes in 
indices of global DNA methylation.76;77  We received ancillary funding to longitudinally follow 
methylation changes examined in the placenta and serial buccal smears from offspring of 
smokers, and to determine if there are methylation changes that are blocked by maternal 
vitamin C supplementation and which appear to associate with decreased risk of asthma.  This 
will allow functional connection of the methylation changes with mechanisms underlying asthma 
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development. This ancillary study is funded by catalyst funding through the Oregon Clinical and 
Translational Research Institute from OHSU.  
 
 
Discussion  
VCSIP is designed to determine if prenatal vitamin C supplementation (500mg/day) 
administered to women unable to quit smoking during pregnancy can increase the pulmonary 
function tests/ FEFs of their offspring measured at 3 months of age as compared to the 
pulmonary function tests from offspring of placebo allocated women. Its secondary outcomes 
evaluate the ability of supplemental vitamin C to decrease the incidence of wheeze in their 
offspring through 12 months of age and to improve the forced expiratory flows of the offspring at 
12 months of age. Multiple studies clearly show that maternal smoking during pregnancy leads 
to altered lung development manifested by impaired pulmonary function and reflected by 
increased respiratory illness in early life.17;20;78  Adverse respiratory outcomes related to 
maternal smoking during pregnancy track from childhood and into adulthood.
2 VCSIP uniquely 
intervenes in utero, a critical time period for lung development, and measures the response to 
vitamin C exposure through infant FEFs, a sensitive measure of peripheral airway function.20;34 
Strengths of our trial include a low-risk and simple yet novel intervention to potentially block the 
harmful effects of nicotine during fetal lung development, and quantification of lung function with 
skilled infant pulmonary function tests.  
Most pregnant smokers will continue to smoke and given nicotine’s addictive nature, the 
low socio-economic status of the study population, and the constant advertising by tobacco 
companies, smoking during pregnancy will continue to adversely affect millions of babies 
worldwide. Statistics from the Center for Disease Control show that decreases in smoking rates 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
have plateaued79 and even increased in recent years for teenagers.80  Multiple studies have 
shown, that upon learning of pregnancy, approximately 50% of smokers will immediately quit; 
the other 50% will continue to smoke no matter the intervention.9  This unfortunate reality makes 
finding ways to lessen the impact of smoking during pregnancy of vital importance. Smoking 
cessation remains our foremost goal, and another strength of VCSIP is that smoking cessation 
counseling continues throughout the study. Only women truly unable to quit smoking are 
involved in the study. If a woman quits smoking after randomization, this is noted and they are 
instructed to continue to participate in the study, as the analytic design is intention-to-treat.  
The strengths of VSCIP include the application of infants PFTs to quantify the infant’s 
physiologic response to the intervention and the correlation to clinical respiratory outcomes. 
Longitudinal studies 69;81;82 have demonstrated that PFTs can quantify the “root” i.e. beginning of 
infant lung disease, and patients who begin life with PFTs below the median continue to track 
below the median throughout life with increased wheezing, asthma and a predisposition to the 
development of chronic obstructive pulmonary disease as the normal aging process occurs. Our 
initial study showed that vitamin C significantly improved the PFTs of newborns born to 
randomized pregnant smokers and that these offspring also showed a lower incidence of 
wheezing at 1 year of age. In addition, VCSIP is powered at a minimum of 90% power for the 
pulmonary function outcomes and between 80 to 90% power for the clinical outcome of the 
incidence of wheezing.   
Limitations include a knowledge gap regarding the ideal time to initiate the vitamin C 
supplementation to block the effects of in utero smoke on the offspring’s lung function. However, 
data from our initial study supports that 23 weeks gestation may be early enough for vitamin C 
supplementation to improve PFTs. There is also animal data83 to support that the critical period 
of exposure to nicotine in terms of impacting lung development is mid gestation, and all of our 
patients will be randomized prior to that time period. Ideally, VSCIP would have multiple study 
arms to assess different combinations of in utero and postnatal exposure to vitamin C 
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supplementation with and without smoke exposure, but this is not practical. Postnatal maternal 
smoking and offspring exposures to environmental smoke are carefully documented through 1 
year of age and the randomization design will allow VCSIP investigators to compare postnatal 
exposures between treatment groups. Lastly, VSCIP  is designed to follow offspring through 1 
year of age. As a clinically relevant asthma diagnosis usually occurs at more than 5 years of 
age, we intend to follow the cohort through 5 years of age. 
The VSCIP study has successfully incorporated important ancillary objectives. In 
particular, genotype likely plays a key role in the development of asthma, the sensitivity to 
maternal smoking, and the difficulty in quitting smoking. Common deletions or structural 
polymorphisms in the glutathione transferase (GST) genes increase both the risk of asthma and 
the sensitivity of the fetus to maternal smoking.63;84-87 The D398N (rs16969968) structural 
polymorphism of the α5 nicotinic receptor increases nicotine addiction, makes quitting more 
difficult, increases the risk of lung cancer and COPD 88 and has been associated with increased 
growth retardation in offspring.89;90 These ancillary studies will assist in elucidating mechanistic 
links between vitamin C supplementation and offspring pulmonary function and potential genetic 
factors associated with high rates of maternal smoking in this patient population. 
VSCIP will provide critical information regardless of whether a difference in pulmonary 
function tests is observed at three months post-delivery between randomized groups. However 
our initial trial of vitamin C supplementation to pregnant smokers is very supportive for a positive 
result in the present VCSIP. In addition, the VCSIP prospective cohort of offspring of pregnant 
smokers is also uniquely phenotyped prenatally and postnatally to address important scientific 
questions related to maternal smoking and childhood respiratory health, which is highly relevant 
to the overall goals of NHLBI, and thus can have a major impact upon public health. 
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Table 3. Summary of procedures in VCSIP 
Study Visit 
(weeks 
gestation) 
Enrollme
nt 
(12 to 
<22) 
Randomizati
on 
(13 to < 23) 
Month
ly 
visits 
 2
nd 
trimest
er 
 (24 to 
28 ) 
Month
ly 
visits 
3
rd
 
trimest
er 
(30 to 
34) 
Delive
ry 
3 
month
s 
after 
deliver
y 
12 
month
s  
after 
deliver
y 
Health/Medi
cal History 
X         
Demographi
c 
Information 
X         
Height, 
weight, 
blood 
pressure 
X X X X X X X   
Smoking 
questionnair
e 
X X X X X X X   
Fasting 
plasma 
ascorbic 
acid 
1
 
 X  X  X    
Urine for 
cotinine 
 X  X  X    
Blood/urine 
for 
biorepositor
y 
2
 
 X  X  X    
Exhaled 
carbon 
monoxide 
3
 
 X  X  X  X X 
Maternal 
hair for 
nicotine  
 X     X X X 
Adverse 
events 
 X X X X X X   
Umbilical 
cord blood 
1, 
2
 
      X   
Placenta 
samples 
      X   
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1 Blood for ascorbic acid (1 green top heparin tube) 
2 Blood for DNA extraction and genotyping (2 purple top tubes)  
3 Measured with Smokelyzer, Bedfont Scientific, London, UK 
4 For DNA extraction and genotyping 
Infant hair 
for nicotine 
      X X X 
Infant 
buccal 
swabs
4
 
      X X X 
Pulmonary 
function test 
       X X 
Respiratory 
questionnair
e (quarterly) 
       X X 
Ages & 
stages 
questionnair
e on infant 
        X 
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